BPC157 Peptide: Public Research Summary & Evidence Review
Disclaimer: All content on this site is an educational summary of public academic and industry research, compiled for informational reference only. It is not medical or laboratory advice. No treatment, health, or purchasing decisions should be made based solely on website content. This site does not sell peptides, does not link sellers, and does not endorse any vendor or any use of any compound.
Definition and core facts
bcp157 peptide is BPC-157: a synthetic 15-residue pentadecapeptide, sequence GEPPPGKPADDAGLV (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val), described in the literature as a fragment of the human gastric juice protein BPCG. It has no terminal modifications beyond the free N-terminus and free acid C-terminus — an unassuming sequence that became one of the most-searched research peptides of the decade.
The evidence base is the central fact of its public research record. The overwhelming majority of published BPC-157 studies are rodent studies — from Croatian laboratories in the early 2000s onward — reporting effects on wound healing, angiogenesis, tendon-to-bone models and gastrointestinal protection. Human trial publications are scarce; no major regulator has approved BPC-157 for any indication; and it appears on prohibited lists in sport. Research suggests promise in specific model systems; published data does not exist at the human-trial tier for the uses discussed in public forums. Both halves of that sentence are documented.
Structure and mechanism
Mechanistically, the published literature reports effects on angiogenesis (VEGF and angiogenic pathways), fibroblast activity, and nitric-oxide-related systems, with a dopaminergic interaction documented in some CNS models. What the field lacks is a single accepted receptor or target — the mechanism literature is phenotypic rather than molecular, which is why effect claims travel faster than understanding. Sequence notes: the proline-rich middle is notable but no special chemistry (cyclization, caps) distinguishes BPC-157 — contrast the engineered modifications on mt2 peptide or the incretin analogs in the science pillar.
Stability and administration in the rodent literature include oral activity claims — unusual for a 15-mer — and long experimental use in models. As with every page here: documented observations, not usage guidance.
How it is measured and used in research
The research-market status follows the pattern documented across the vendor pillar: BPC-157 is sold as a research chemical across the gray market, with certificate quality spanning the full documented range. The five-field COA standard and independent-confirmation search apply to any lot; mass confirmation checks the 1,419 Da monoisotopic mass of the sequence (arithmetic on the structure page).
Evidence grading for the biology: rodent-model publications Tier 2 (peer-reviewed but pre-clinical); in-vitro work Tier 2; human data effectively absent from the graded record; regulatory status Tier 1 (prohibited lists, non-approval). The grading discipline is the editorial policy this site applies everywhere.
Research context and related pages
Related research-compound case studies: mt2 peptide (unapproved, phenotypic evidence), tesamorelin peptide (approved, full clinical evidence) — together they bracket the evidence spectrum a peptide name can occupy.
The foundations — what a 15-residue chain is, its bonds, its measurement — live on the chain structure, peptide bond and analysis pages; the hub for all of them is the peptide science & research pillar.
How to use the data on this page
Step 1 — extract the parameters. Extract: sequence, 15-residue length, source protein (BPCG fragment), evidence tier of any claim encountered (rodent / in-vitro / human).
Step 2 — normalize before comparing. Normalize: never compare BPC-157 effect claims across species or administration routes without noting the model; the record is rodent-dominated.
Step 3 — grade the source. Grade: rodent publications Tier 2; human trials largely absent; regulator non-approval Tier 1.
Parameter comparison
The BPC-157 public research record, tiered.
| Evidence element | Status | Tier |
|---|---|---|
| Sequence / identity | GEPPPGKPADDAGLV, 15 residues, ~1,419 Da mono | Tier 1 |
| Primary literature | Predominantly rodent models | Tier 2 |
| Human trials | Scarce to absent in public record | Gap |
| Regulatory status | Not approved; sport prohibited lists | Tier 1 |
| Accepted receptor/target | Not established | Open question |
Table: The BPC-157 public research record, tiered. — compiled from public regulatory and academic sources; verify against the original documents before use.
Frequently asked questions
What is bpc157 peptide used for?
In the published literature, BPC-157 has been studied in rodent models of wound healing, tendon and ligament injury, angiogenesis and gastrointestinal protection. It is not approved for any human use by any major regulator, human trial data are scarce, and it appears on sport prohibited lists. This site documents that record and makes no usage recommendation.
References
- Sikiric P et al. The influence of a novel pentadecapeptide BPC 157 on healing of transected tendon... (Croatian BPC-157 literature lineage, Tier 2).
- WADA prohibited list (non-approved substances).
- Peptide sequence and mass references (UniProt BPCG fragment context).